Biogen: The Alzheimer's Comeback Story Wall Street Can't Ignore
Strong stock · S&P 500 · Biogen Inc. (BIIB) · Analysis as of 2026-09-04
After years of pipeline frustration, Biogen is writing a new chapter — and the numbers are finally backing it up. With a blockbuster Alzheimer's franchise gaining global traction, a surging growth portfolio, and upgraded guidance that caught analysts off guard, this neuroscience heavyweight is demanding a second look.
Something rare is happening at Biogen. A company once written off as a one-trick multiple sclerosis play is now delivering on a multi-product growth story — and the market is starting to pay close attention.
The Fundamental Turnaround: Growth Where It Counts
Biogen's most recent quarterly results told a compelling story. Total revenue reached $2.74 billion, rising 3% year over year, while core pharmaceutical revenue climbed to $1.8 billion — up 4% annually and a striking 12% sequentially. The standout headline, however, was the growth portfolio: revenues surpassing $1 billion, representing a 24% year-over-year surge. This is no longer a company coasting on legacy assets.
The growth engines are firing on multiple cylinders:
| Product | Quarterly Revenue | Year-over-Year Growth | |---|---|---| | LEQEMBI (lecanemab) | $184M | +15% | | SKYCLARYS | $168M | +29% | | SYFOVRE | $162M | +8% | | EMPAVELI | $46M | +123% | | Anti-CD20 Royalties | $514M | +10% |
Management raised full-year 2026 revenue guidance from an anticipated mid-single-digit decline to a mid-single-digit increase — a dramatic pivot that materially altered the market's earnings calculus. Non-GAAP diluted EPS is now guided in the $12–$13 range for the full year.
LEQEMBI: The Global Alzheimer's Franchise Expanding Fast
LEQEMBI, Biogen's co-developed Alzheimer's therapy with Eisai, is emerging as a true global franchise. The drug has now been approved in 53 countries and regions, with regulatory review active in six more. The catalyst pipeline is particularly rich: China's NMPA approved the subcutaneous formulation of lecanemab — a more patient-friendly administration route — while Canada issued a positive recommendation. These international approvals broaden the addressable market meaningfully and reduce Biogen's historical over-reliance on the U.S. market.
Adding further tailwind, lecanemab was included in China's Commercial Insurance Innovative Drug List — a development that could accelerate patient uptake in the world's most populous market.
Apellis: A Portfolio Diversifier With Upside
Biogen's acquisition of Apellis has added two ophthalmology assets — SYFOVRE and EMPAVELI — that are rapidly scaling. EMPAVELI's 123% revenue growth reflects early-stage commercial momentum, while SYFOVRE's steady expansion in geographic atrophy (GA) positions Biogen in one of ophthalmology's fastest-growing disease areas. Management has guided for the acquisition to be accretive in 2027, suggesting the integration is on track.
Valuation: Fairly Priced for a Rare Disease Growth Story
At a closing price of $220.83, Biogen trades at a P/E of 39.15 and a PEG ratio of 1.13. In biotech terms, a PEG close to 1.0 suggests the market is not dramatically overpaying for expected earnings growth — particularly notable given the multi-product portfolio momentum. The guidance raise implies earnings estimate revisions may still have room to run, which could provide a valuation floor.
Technical Perspective: Momentum Constructive
From a technical standpoint, BIIB's price action reflects a stock building institutional interest. The 90-day price return has been solidly positive, with the stock recovering meaningfully from prior lows. The 1-year total shareholder return of approximately 62% reflects a trend shift that technical analysts typically associate with sustained accumulation. Price consolidation near recent highs — rather than sharp reversals — often signals institutional positioning rather than speculative activity.
Analyst Sentiment Turns Constructive
Wall Street's tone has shifted. Truist Securities raised its price target to $235, while Piper Sandler followed with a target of $245 — among the more bullish calls in recent coverage. With multiple sell-side desks upgrading outlooks following the guidance raise, the analyst community's revised expectations suggest a broader reappraisal of Biogen's earnings trajectory is underway.
The Takeaway
Biogen is no longer a story of potential — it is a story of execution. A diversified neuroscience and rare disease portfolio, a globally expanding Alzheimer's franchise, a strategically sound acquisition integrating ahead of schedule, and a guidance raise that reset expectations higher: these are the building blocks of a genuine investment thesis. The PEG ratio suggests the market hasn't yet fully priced in the growth trajectory. In a sector where catalysts are rare, Biogen appears to have several in hand.
--- Disclaimer: This article is for educational purposes only and does not constitute financial advice. Please consult a qualified financial advisor before making any investment decisions.